FGFR2 NGS Gene Fusion

Disease Application:
  • Cholangiocarcinoma
Test Performance Characteristics:
  • 1. PT Accuracy of Testing: Correct detection of the ‘known’ fusion by NGS. 2. Post-analytical Accuracy: Correct reporting of any detected fusions. Review of annotation paragraph for correct statements regarding clinical implications of FGFR2 fusions.
  • Next Generation Sequencing (NGS) for Gene Fusion Detection (using RNA or DNA)
Registration is due on May 25, 2023, with cases sent out to all registrants in June, 2023
The run will end on:
  • 21 August 2023
The run results from each laboratory must be submitted to CBQA by:
  • 20 September 2023
The current status for this run:
  • Enrolment Phase

You must have joined CBQA and be logged in to enrol.